Skip to content
OpenCapital
Get started

ADC Therapeutics ADCT Q1 2026 earnings

Reported May 4, 2026 · Before market open

Revenue$20.9MBeat by $864.2K
EPS-$0.21Miss by $0.02
Revenue estimate$20.0M
EPS estimate-$0.19

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$18.9M
EPS estimate-$0.19

Versus estimates

Revenue

Q1 2026$20.9MBeat by $864.2K
Q4 2025$23.1MBeat by $757.8KQ3 2025$16.4MMiss by $5.1MQ2 2025$18.8MBeat by $645.5KQ1 2025$23.0MBeat by $5.5MQ4 2024$16.9MMiss by $2.1M

Diluted EPS

Q1 2026-$0.21Miss by $0.02
Q4 2025-$0.04Beat by $0.28Q3 2025-$0.30Beat by $0.10Q2 2025-$0.50Miss by $0.14Q1 2025-$0.36Beat by $0.02Q4 2024-$0.29Beat by $0.06

Ask the moment ADC Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ADC Therapeutics report Q1 2026 earnings?
ADC Therapeutics (ADCT) reported Q1 2026 earnings on May 4, 2026 before market open.
What were ADC Therapeutics's Q1 2026 revenue and EPS?
ADC Therapeutics reported revenue of $20.9M and eps of $-0.21 for Q1 2026.
Did ADC Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $20.0M by $864.2K. EPS missed the consensus estimate of $-0.19 by $0.02.
How did ADC Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 9.5% from $23.0M a year earlier and eps grew 41.7% from $-0.36.
Where can I find ADC Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-029524) and the 10-Q periodic report (0001628280-26-029819) directly on SEC EDGAR. The filing index links above go to sec.gov.